Late-breaking, head-to-head results reinforce potential of zasocitinib as a next-generation TYK2 inhibitor (Takeda Press Release) - Sep 30, 2026 - "Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026...36.5% of patients treated with zasocitinib (n=301) achieved complete skin clearance (Psoriasis Area and Severity Index (PASI) 100) at week 16 versus 13.9% in the deucravacitinib group (n=303; p<0.001); 62.5% of patients treated with zasocitinib achieved PASI 90 at week 16 versus 34.0% in the deucravacitinib group (p<0.001);
43.2% of patients treated with zasocitinib achieved clear skin (static Physician Global Assessment (sPGA) 0) at week 16 versus 18.5% in the deucravacitinib group (p<0.001); Zasocitinib was generally well-tolerated with no new safety signals identified."
Late-breaking abstract • P3 data • Immunology • Plaque Psoriasis
|